NasdaqGM - Nasdaq Real Time Price USD
Protagonist Therapeutics, Inc. (PTGX)
As of 1:06 PM EST. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
319,120.00
60,000.00
26,581.00
27,357.00
28,628.00
Operating Expense
166,881.00
153,652.00
157,954.00
153,202.00
93,144.00
Operating Income
152,239.00
-93,652.00
-131,373.00
-125,845.00
-64,516.00
Net Non Operating Interest Income Expense
20,274.00
14,898.00
4,060.00
443.00
302.00
Other Income Expense
91.00
-201.00
-80.00
-149.00
-631.00
Pretax Income
172,604.00
-78,955.00
-127,393.00
-125,551.00
-64,845.00
Tax Provision
--
--
--
--
1,305.00
Net Income Common Stockholders
169,954.00
-78,955.00
-127,393.00
-125,551.00
-66,150.00
Diluted NI Available to Com Stockholders
169,954.00
-78,955.00
-127,393.00
-125,551.00
-66,150.00
Basic EPS
2.84
-1.39
-2.60
-2.71
-1.92
Diluted EPS
2.72
-1.39
-2.60
-2.71
-1.92
Basic Average Shares
60,457.82
56,763.56
49,042.23
46,322.91
34,396.45
Diluted Average Shares
61,872.39
56,763.56
49,042.23
46,322.91
34,396.45
Total Operating Income as Reported
152,239.00
-93,652.00
-131,373.00
-125,845.00
-64,516.00
Total Expenses
166,881.00
153,652.00
157,954.00
153,202.00
93,144.00
Net Income from Continuing & Discontinued Operation
169,954.00
-78,955.00
-127,393.00
-125,551.00
-66,150.00
Normalized Income
169,954.00
-78,955.00
-127,393.00
-125,551.00
-65,722.95
Interest Income
20,274.00
14,898.00
4,060.00
443.00
900.00
Interest Expense
--
--
--
--
598.00
Net Interest Income
20,274.00
14,898.00
4,060.00
443.00
302.00
EBIT
152,239.00
-93,652.00
-131,373.00
-125,845.00
-64,247.00
EBITDA
155,610.00
-90,340.00
-128,004.00
-123,070.00
-61,524.00
Reconciled Depreciation
3,371.00
3,312.00
3,369.00
2,775.00
2,723.00
Net Income from Continuing Operation Net Minority Interest
169,954.00
-78,955.00
-127,393.00
-125,551.00
-66,150.00
Total Unusual Items Excluding Goodwill
--
--
--
--
-585.00
Total Unusual Items
--
--
--
--
-585.00
Normalized EBITDA
155,610.00
-90,340.00
-128,004.00
-123,070.00
-60,939.00
Tax Rate for Calcs
0.00
--
--
--
0.00
Tax Effect of Unusual Items
--
--
--
--
-157.95
12/31/2020 - 8/11/2016
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MRUS Merus N.V.
54.54
+0.06%
EWTX Edgewise Therapeutics, Inc.
36.43
+2.82%
ACLX Arcellx, Inc.
105.03
+5.92%
VERA Vera Therapeutics, Inc.
47.57
-3.00%
CRNX Crinetics Pharmaceuticals, Inc.
59.77
-0.07%
ANAB AnaptysBio, Inc.
21.23
-1.23%
JANX Janux Therapeutics, Inc.
54.88
+1.24%
APGE Apogee Therapeutics, Inc.
61.13
+5.30%
ASND Ascendis Pharma A/S
124.98
-1.24%
IDYA IDEAYA Biosciences, Inc.
30.87
+2.93%